HLL Lifecare Ltd
HLL Lifecare Ltd
News Article | May 11, 2017
— In this report, the global Condoms market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Condoms for these regions, from 2012 to 2022 (forecast), covering United States China Europe Japan Southeast Asia India Global Condoms market competition by top manufacturers/players, with Condoms sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including Karex Thai Nippon Rubber TTK-LIG HLL Lifecare Suretex(Ansell) Qingdao Durex Guilin Latex Unidus Corp Doubleone Latex Pleasure Latex SSL(Thailand) Okamoto Suretex India(Ansell) Church&Dwight Nulatex Sdn Bhd J.K. Ansell Dalian Latex Double Butterfly Angel Latex Human-care Latex MINGBAN HBM Xibei On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into Latex Condom Non-latex Condom On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Condoms for each application, including Age: Under 25 Age: 25-34 Age: 35-49 Age: Above 50 Table of Content: Key Points Global Condoms Sales Market Report 2017 1 Condoms Market Overview 1.1 Product Overview and Scope of Condoms 1.2 Classification of Condoms by Product Category 1.2.1 Global Condoms Market Size (Sales) Comparison by Type (2012-2022) 1.2.2 Global Condoms Market Size (Sales) Market Share by Type (Product Category) in 2016 1.2.3 Latex Condom 1.2.4 Non-latex Condom 1.3 Global Condoms Market by Application/End Users 1.3.1 Global Condoms Sales (Volume) and Market Share Comparison by Application (2012-2022) 1.3.2 Age: Under 25 1.3.3 Age: 25-34 1.3.4 Age: 35-49 1.3.5 Age: Above 50 1.4 Global Condoms Market by Region 1.4.1 Global Condoms Market Size (Value) Comparison by Region (2012-2022) 1.4.2 United States Condoms Status and Prospect (2012-2022) 1.4.3 China Condoms Status and Prospect (2012-2022) 1.4.4 Europe Condoms Status and Prospect (2012-2022) 1.4.5 Japan Condoms Status and Prospect (2012-2022) 1.4.6 Southeast Asia Condoms Status and Prospect (2012-2022) 1.4.7 India Condoms Status and Prospect (2012-2022) 1.5 Global Market Size (Value and Volume) of Condoms (2012-2022) 1.5.1 Global Condoms Sales and Growth Rate (2012-2022) 1.5.2 Global Condoms Revenue and Growth Rate (2012-2022) … 9 Global Condoms Players/Suppliers Profiles and Sales Data 9.1 Karex 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Condoms Product Category, Application and Specification 22.214.171.124 Product A 126.96.36.199 Product B 9.1.3 Karex Condoms Sales, Revenue, Price and Gross Margin (2012-2017) 9.1.4 Main Business/Business Overview 9.2 Thai Nippon Rubber 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Condoms Product Category, Application and Specification 188.8.131.52 Product A 184.108.40.206 Product B 9.2.3 Thai Nippon Rubber Condoms Sales, Revenue, Price and Gross Margin (2012-2017) 9.2.4 Main Business/Business Overview 9.3 TTK-LIG 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Condoms Product Category, Application and Specification 220.127.116.11 Product A 18.104.22.168 Product B 9.3.3 TTK-LIG Condoms Sales, Revenue, Price and Gross Margin (2012-2017) 9.3.4 Main Business/Business Overview 9.4 HLL Lifecare 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Condoms Product Category, Application and Specification 22.214.171.124 Product A 126.96.36.199 Product B 9.4.3 HLL Lifecare Condoms Sales, Revenue, Price and Gross Margin (2012-2017) 9.4.4 Main Business/Business Overview 9.5 Suretex(Ansell) 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Condoms Product Category, Application and Specification 188.8.131.52 Product A 184.108.40.206 Product B 9.5.3 Suretex(Ansell) Condoms Sales, Revenue, Price and Gross Margin (2012-2017) 9.5.4 Main Business/Business Overview 9.6 Qingdao Durex 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Condoms Product Category, Application and Specification 220.127.116.11 Product A 18.104.22.168 Product B 9.6.3 Qingdao Durex Condoms Sales, Revenue, Price and Gross Margin (2012-2017) 9.6.4 Main Business/Business Overview 9.7 Guilin Latex 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Condoms Product Category, Application and Specification 22.214.171.124 Product A 126.96.36.199 Product B 9.7.3 Guilin Latex Condoms Sales, Revenue, Price and Gross Margin (2012-2017) 9.7.4 Main Business/Business Overview 9.8 Unidus Corp 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Condoms Product Category, Application and Specification 188.8.131.52 Product A 184.108.40.206 Product B …Continued For more information, please visit http://www.wiseguyreports.com
Kumaran A.,HLL Lifecare Ltd. |
Ho C.C.,National Taiwan University of Science and Technology |
Hwang L.S.,National Taiwan University of Science and Technology
Journal of Food and Drug Analysis | Year: 2017
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. β-Amyloid (Aβ) has been proposed to play a role in the pathogenesis of AD. Deposits of insoluble Aβ are found in the brains of patients with AD and are one of the pathological hallmarks of the disease, but the underlying signaling pathways are poorly understood. In order to develop antidementia agents with potential therapeutic value, we examined the inhibitory effect of the Nelumbo nucifera seed embryo extracts on to the aggregated amyloid β peptide (agg Aβ1-40)-induced damage of differentiated PC-12 cells (dPC-12), a well-known cell model for AD. In the present study, seed embryos of N. nucifera were extracted with 70% methanol in water and then separated into hexane, ethyl acetate, n-butanol, and water layers. Among them, only the n-butanol layer showed strong activity and was therefore subjected to separation on Sephadex LH-20 chromatography. Two fractions showing potent activity were found to significantly inhibit Aβ1-40 toxicity on dPC-12 cells in increasing order of concentration (10-50 μg/mL). Further purification and characterization of these active fractions identified them to be flavonoids such as rutin, orientin, isoorientin, isoquercetrin, and hyperoside. 2,2-Diphenyl-1-picrylhydrazyl hydrate scavenging activity of the extracts was also carried out to ascertain the possible mechanism of the activity. © 2017.
Shukla S.K.,HLL Life care Ltd
Redox Report | Year: 2015
Objective: This study was aimed to evaluate the cardioprotective potential of combination of T. arjuna and α-tocopherol in isoproterenol induced myocardial injury. Methods: Wistar albino rats were pre-treated with hydroalcoholic extract of T. arjuna (HETA) and α-tocopherol (100 mg/kg b. w) daily for 30 days. Isoproterenol (ISP, 85 mg/kg b.w) was administered on 28th and 29th days at an interval of 24 hr. Results: ISP treated rats showed significant increase in lipid peroxidation (MDA), cardiac markers (CK-MB, SGOT, Trop I and LDH), pro-inflammatory cytokine (IL-6, CRP, TNF-α) levels and apoptotic markers (Bcl-2/ Bax) as compared to healthy group. Pre-treatment with HETA 100 mg/kg b. w, reduced the elevated levels of these markers and significant effect (p<0.05) were observed with the combination of HETA and α-tocopherol at a dose of 100 mg/kg b. w, which was further confirmed by histopathological studies. Conclusion: The present study concluded that the combination of α-tocopherol (100 mg/kg b. w) and hydroalcoholic extract of T. arjuna (100 mg/kg b. w) augments endogenous antioxidant compounds of rat heart and also prevents the myocardium from ISP-induced myocardial injury and it may have therapeutic and prophylactic value in the treatment of ischemic heart disease. © W. S. Maney & Son Ltd 2015.
Kavitha Sankar P.C.,HLL Lifecare Ltd. |
Rajmohan G.,HLL Lifecare Ltd. |
Rosemary M.J.,HLL Lifecare Ltd.
Materials Letters | Year: 2017
Haemorrhage is one of the most common cause of mortality if proper action is not taken in a fixed period of time. Over the past three decades, usage of haemostatic materials have been widely introduced for arresting the bleeding. Chitosan is one of the biopolymer which is widely used as a haemostatic agent cross linked using glutaraldehyde and freeze dried to prepare a spongy haemostat. The process of freeze drying has been optimised in a controlled freeze dryer in such a way that we obtain a sponge having good mechanical strength as well as blood absorbing capacity. The morphology and microstructure of the chitosan sponge was observed by scanning electron microscopy (SEM). The chitosan sponge was sterilised using gamma irradiation and sterility studies were carried out to prove the sterile nature of the material. In-vitro cytotoxicity evaluation; in vivo intracutaneous reactivity and Guinea pig maximization test conducted on the gamma irradiated chitosan sponge proved the safety of the chitosan sponge to be suitable for haemostasis. © 2017.
News Article | December 14, 2016
U.S. design firm IXu LLC confirms today that patent licensing talks are in progress between IXu and female condom manufacturer Cupid Ltd. of Nashik, India. “IXu was approached by Cupid with their interest to obtain exclusive licensing rights to our patents,” states IXu CEO Brian Osterberg. “The IXu patents, currently being developed under the women’s condom brands VA wow and VA Vibe, should drastically increase the global female condom market.” Osterberg also states, “Our patents focus on miniaturized stimulation accessories attached to conventional female condoms, in essence creating a female condom/sextoy combination product.” Current product development and production for IXu is being done at HLL Lifecare Ltd. and Indus Medicare Ltd., both of India. “IXu looks at Cupid as a potential partner to develop more sophisticated next-generation female condoms,” states Osterberg. Cupid Ltd. is one of four major female condom manufacturers. Cupid’s Bombay Stock Exchange share price rose from 9 to 475 during 2014 to 2015. Cupid was rated a 2016 Forbes Top 200 Asian Under a Billion. “Our revolutionary female condom/sex toy hybrid (VA Vibe) proved extremely successful, with a very high female orgasm rate, in an independent 50-couple User Survey conducted by Prastut Consulting of India. The demand for these worn-of-women vibe condoms is real and we will enter global distribution in 2017,” states Osterberg. On the conventional female condom side with IXu, one early European test-market of the VA wow included the Portuguese Health Ministry. The ministry chose to purchase only the VA wow brand female condom for all its national clinics – – after an initial year of offering both the VA wow and the FC2 female condoms to the entire population in all clinics. The VA wow model achieved the highest overall rating in efficacy when compared to the Cupid, FC2 and PATH brands in a 2013 clinical study of performance. The Lancet medical journal published the results of the clinical study funded by UAFC, Universal Access to Female Condoms. See ixullc.com for the full Clinical Study results. The VA Vibe model was showcased on CNN’s Dr. Drew show and critically acclaimed by Cosmopolitan, Glamour, Men’s Fitness, The Mirror, The Guardian, mic.com, etc., and other writers from the U.S., Britain, France, Germany, Australia, Italy, etc. IXu designs have 20-years market presence globally and are well-known in the male and female condom industry. IXu developed the world’s media and consumer-rated number #1 inSpiral male condom. Previously sold at Walgreens, Boots, CVS Drugs, Walmart, etc., and preparing for a “new and improved” global relaunch. IXu also holds the U.S. Design Patent for the curved “banana-shaped” male condom, which Durex® marketed briefly in the USA. IXu LLC is a design firm founded in the USA in 1998.
News Article | November 28, 2016
While sexual health is an important part of a person's body, the field doesn't always receive the research needed to give the world better products. The Gates Foundation tried to solve that problem by offering awards to the best proposals for the "next generation of condom" back in 2013. The foundation funded 11 condom-related projects with $100,000 each, and chosen proposals ranged from one-size-fits-all condoms to ones that could be put on in "one motion" without interrupting intercourse. "Quite simply, condoms save lives but new thinking is needed to ensure that men and women around the world are using them consistently and correctly to prevent unwanted pregnancies and sexually transmitted infections," the Gates Foundation said in a press release. That was three years ago this week. So what happened to those ideas? They're still being created. Development and Federal Drug Administration approval takes years, if not a decade, and much more money than one award can provide. But that doesn't mean these mavens of sexual health are sitting on their laurels in the meantime. Read More: I Tried the Latest In Condom Technology and It Went Shockingly Well Patrick Kiser of Northwestern University is working on developing a condom that acted similarly to mucosal tissue, a membrane that lines several body parts including the vagina and parts of the penis, to improve sensation. In the meantime, he was part of a team that developed an intra-vaginal ring that acts as birth control and releases a medicine to treat HIV/AIDS. The ring, which contains the anti-retroviral drug tenofovir, has the potential to help women in the developing world avoid pregnancy and treat HIV without the daily pills that are currently on the market. It is awaiting FDA approval. Another project funded by the Gates Foundation was a plan by Lakshminarayanan Ragupathy of HLL Lifecare Ltd. to create a condom with a graphene layer that could heat up to regular body temperature and act as a drug delivery system for STD prevention. The condom is still under development, but Ragupathy later received a $1 million grant from the Gates Foundation to continue pursuing this project once it showed some results, Vice reported earlier this year. He later began work on a project to develop a biodegradable condom that is odorless and compatible with antiviral drugs and other contraceptives. Since latex condoms take several years to biodegrade in landfills, some consumers opt for eco-friendly condom options like natural lambskin condoms, with higher price tags. Willem van Rensburg of Kimbranox Ltd. was awarded a Gates Foundation award for his idea to create a device that puts on a male condom in one motion without interrupting sex. The Rapidom, as the device is called, was meant to avoid all the fuss that goes into removing a condom from its wrapper and putting it on properly—which is sometimes cited by men as a reason why they don't use condoms at all. "Manual application of condoms takes time, which can lead to incorrect positioning as it interrupts the sexual act, and current applicators require good technique," van Rensburg's proposal reads. His goal has been to stem the tide of HIV/AIDS infections that have swept across his home country of South Africa. An early version of the applicator is available in South Africa under the name Pronto Condoms, but an Indigogo crowdfunding campaign only raised $800. The U.S. will, unfortunately, have to wait its turn. Get six of our favorite Motherboard stories every day by signing up for our newsletter.
Jose A.J.,Anna University |
Alagar M.,Anna University |
Aprem A.S.,HLL Lifecare Ltd
International Journal of Polymeric Materials and Polymeric Biomaterials | Year: 2012
Organo-modified fluorohectorite (OFH) clay-filled polysulfone (PSf) nanocomposites were prepared by a solution casting method. The dispersion of OFH clay in PSf nanocomposites was investigated using X-ray diffraction (XRD), atomic force microscopy (AFM), and transmission electron microscopy (TEM). Thermal analysis revealed that incorporation of organoclay increased the thermal stability and glass transition temperature (Tg) of nanocomposites. The barrier properties of the nanocomposites studied were found to be significantly improved. It is worth mentioning that the improved thermal stability and barrier performance of these nanocomposites with the addition of organoclay in PSf matrix obviously offers immense potential in industrial and automobile applications. © 2012 Copyright Taylor and Francis Group, LLC.
Rai B.,Oncology and Radiotherapy Institute |
Patel F.D.,Oncology and Radiotherapy Institute |
Chakraborty S.,Oncology and Radiotherapy Institute |
Sharma S.C.,Oncology and Radiotherapy Institute |
And 2 more authors.
International Journal of Radiation Oncology Biology Physics | Year: 2013
Purpose: To compare bladder and rectum doses with the use of a bladder-rectum spacer balloon (BRSB) versus standard gauze packing in the same patient receiving 2 high-dose-rate intracavitary brachytherapy fractions. Methods and Materials: This was a randomized study to compare the reduction in bladder and rectum doses with the use of a BRSB compared with standard gauze packing in patients with carcinoma of the cervix being treated with high-dose-rate intracavitary brachytherapy. The patients were randomized between 2 arms. In arm A, vaginal packing was done with standard gauze packing in the first application, and BRSB was used in the second application. Arm B was the reverse of arm A. The International Commission for Radiation Units and Measurement (ICRU) point doses and doses to 0.1-cm3, 1-cm 3, 2-cm3, 5-cm3, and 10-cm3 volumes of bladder and rectum were compared. The patients were also subjectively assessed for the ease of application and the time taken for application. Statistical analysis was done using the paired t test. Results: A total of 43 patients were enrolled; however, 3 patients had to be excluded because the BRSB could not be inserted owing to unfavorable local anatomy. Thus 40 patients (80 plans) were evaluated. The application was difficult in 3 patients with BRSB, and in 2 patients with BRSB the application time was prolonged. There was no significant difference in bladder doses to 0.1 cm3, 1 cm3, 2 cm3, 5 cm3, and 10 cm3 and ICRU bladder point. Statistically significant dose reductions to 0.1-cm3, 1-cm3, and 2-cm3 volumes for rectum were observed with the BRSB. No significant differences in 5-cm3 and 10-cm3 volumes and ICRU rectum point were observed. Conclusion: A statistically significant dose reduction was observed for small high-dose volumes in rectum with the BRSB. The doses to bladder were comparable for BRSB and gauze packing. Transparent balloons of variable sizes are recommended for patients with a less spacious vaginal cavity. © 2013 Elsevier Inc.
HLL Lifecare Ltd. | Date: 2012-09-25
HLL Lifecare Ltd. | Date: 2013-01-01
Medical devices in the nature of bags for blood collection.